Moncyte Health, a Helsinki, Finland-based company developing proprietary technology to optimize treatment and prevention of cardiovascular disease, raised €1M in Seed funding.
The round was led by Inventure, Almaral, and Athensmed and included funding from University of Helsinki Funds, European investors, and a grant from Business Finland.
The company intends to use the funds to further enhance its go-to-market strategy and development efforts.
Led by CEO Tamara Alagirova, Moncyte Health is developing proprietary technology that provides quantitative insight into the biological processes that give rise to high blood cholesterol and how they are different in individuals. The technology also provides insight for pharmaceutical companies about how novel lipid-lowering drugs influence the cellular processes contributing to cardiovascular risk.
FinSMEs
08/10/2024